Thank you for subscribing!
Finfeed Sep 02, 2022
Our biotech Investment and 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), has been busy this year working towards its all important Phase 3 trial and first interim results. After our initial entry at 20c in August 2021, our Investment in DXB is currently sitting below that price at 14.5 cents.
Finfeed Archived Apr 08, 2020
AVITA Medical Limited (ASX: AVH) is a med-tech stock worth targeting outside the blue chips such as ResMed, CSL and Ramsay Health Care.
Finfeed Archived Mar 03, 2020
Clinical stage regenerative medicine company Regeneus Ltd (ASX:RGS) has signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in the life sciences industry.
Next Investors Archived Mar 02, 2020
Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.
Get expert stock analysis direct in your inbox
Join Our Mailing List
